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20 Running head: Length decline with zinc and iron supplements 
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1 Abstract 
2 Background: High rates of iron deficiency anemia and early linear growth faltering 
3 possibly due to zinc deficiency are observed in infants in the developing world. We 
4 recently demonstrated that microencapsulated ferrous fumarate sprinkles were efficacious 
5 in the treatment of anemia, yet infants manifested a rapid decline in linear growth. Since 
6 iron supplementation can depress zinc absorption we speculated that the growth faltering 
7 might be due to zinc deficiency. 
8 Objective: To determine the effect of zinc supplementation on linear growth in anemic 
9 infants treated with microencapsulated ferrous fumarate. 
10 Design: In a prospective randomized double-masked clinical trial, we studied 304 
11 anemic infants (mean age 10.3 ± 2.5 months; hemoglobin 87.4 ± 8.4 g/L) in rural Ghana. 
12 The intervention group (n= 160) received a daily sachet of microencapsulated ferrous 
13 fumarate (80 mg iron) and zinc gluconate (10 mg) in powder form to be sprinkled on to 
14 any complementary food; the control group (n=144) received an identical sachet without 
15 added zinc. Both groups received the sachets once daily for 2 months. Anthropometric 
16 measurements, plasma zinc, hemoglobin and ferritin were measured at baseline and end. 
17 78.6% of infants completed the study. 
18 Results At baseline, 80.7% of infants had normal plasma zinc concentrations but were 
19 stunted. Stunting significantly worsened alter zinc supplementation (z-score, -1.70 start, 
20 -1.81 end, p=0.001) when compared to the control group (z-score, -1.81 start, -1.86, 
21 p=0.0985). Mean plasma zinc concentration decreased significantly in both groups 
22 (p<0.05). The rate of recovery from anemia was higher in the control group than in the 
23 zinc supplemented group (74.8% (86/115) vs 62.9% (78/124); p = 0.048). 
4 
1 Conclusion Short-term use of zinc supplements in anemic children did not prevent 
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1 Introduction 
2 High prevalence rates for anemia and early linear growth faltering are common 
3 features of malnourished infants in the developing world (1, 2). Both are associated with 
4 diminished cognitive and physical development that may not be reversible (3). Anemia 
5 and stunting are also common consequences of the plant- and cereal-based 
6 complementary diet typically fed to infants and children in developing countries (4). 
7 These complementary foods are low in energy and poor sources of bioavailable iron and 
8 zinc. They are high in phytic acid, which further reduces the absorption of both 
9 micronutrients from the diet. To improve the nutritional status of these infants, it has been 
10 suggested that supplementation with micronutrients may be the most appropriate strategy 
11 (5) 
12 
13 In an effort to improve the iron status of infants, we recently developed a novel 
14 supplementation approach, which provides microencapsulated ferrous fumarate and 
15 ascorbic acid in powder form. Packaged in individual sachets, the supplement is 
16 designed to be sprinkled on to complementary foods alter the food is cooked. In a 
17 randomized controlled trial we demonstrated that microencapsulated ferrous fumarate 
18 sprinkles were as efficacious as ferrous sulfate drops in the treatment of anemia in infants 
19 6-18 months of age (6). Despite the positive effect on anemia status, we observed a rapid 
20 and significant decline in linear growth over the two-month study period. Height-for-age 
21 z-scores in both groups (drops and sprinkles) decreased from a mean of -1.36 ± 1.12 at 
22 the beginning, to -1.53±1.16 at the end of the two-month intervention (p<0.0001) without 
23 concurrent changes in either weight-for-age or weight-for-height z-scores in either group. 
6 
1 We speculated that this rapid decline in linear growth might have been due to a 
2 combination of de novo and iatrogenic zinc deficiency, since linear growth failure in 
3 infants is a principle clinical feature of zinc deficiency (7-10). 
4 
5 The interaction between iron and zinc has been well-described (11-13). At an 
6 estimated molar ratio (Fe:Zn) of >2:1 in adults, iron can depress zinc absorption when 
7 iron is given as a supplement (14). Moreover, iron supplementation has also been 
8 associated with impaired linear growth in Honduran infants (15). To explain the linear 
growth faltering observed among infants in our original study, we speculated that iron 
10 supplementation provided to the infants may have depressed the absorption of 
11 endogenous zinc from primarily cereal-based weaning diet, thereby, exacerbating an 
12 already precarious zinc status. This may have led to the observed rapid decline in linear 
13 growth. 
14 
15 In the prospective double-masked randomized controlled trial reported here, we 
16 tested the hypothesis that anemic infants receiving daily zinc supplementation combined 
17 with microencapsulated ferrous fumarate sprinkles plus ascorbic acid would manifest 
18 improved height-for-age z-scores and plasma zinc concentrations when compared to 
19 anemic infants receiving microencapsulated ferrous fumarate sprinkles with ascorbic acid 
20 alone. Our objective therefore was to determine the effect of zinc supplementation on 
21 linear growth in anemic infants treated with microencapsulated ferrous fumarate. 
7 
1 Methods 
2 Study area, subjects and recruitment 
3 The research took place in the field study area for the Kintampo Health Research 
4 Centre (KHRC), located in the Brong Ahafo Region of Ghana. This is a malaria-endemic 
5 ares where the principle complementary food is a maize-based porridge, low in 
6 bioavailable iron and zinc. The prevalence of anemia in young children is estimated at 
7 about 70%, a significant proportion of which is due to iron deficiency (16). 
8 Eligible infants were identified from an existing surveillance database of births in 
9 the district. To be included in the study, infants had to be 6 to 24 months old at the time 
10 of recruitment; ingesting a weaning food in addition to breast milk; with a hemoglobin 
11 concentration between 70 and 99 g/L, as measured during a baseline assessment. 
12 Children who were severely anemic (hemoglobin <70 g/L) were excluded from the trial 
13 and treated. 
14 
15 Study Design 
16 Since it was unethical to provide a placebo to a child with anemia at the start of the 
17 trial, we did not include a placebo control. Randomization to one of the two treatment 
18 groups was done with sealed opaque envelopes containing group designations, which 
19 were generated randomly by computer with Microsoft Access 97 (Microsoft Corporation, 
20 Seattle, WA). Ail individuals involved in the study (including parents and field workers) 
21 were blinded to group assignments until the code was broken at the completion of the 
22 data analysis. 
8 
1 The intervention group received microencapsulated ferrous fumarate (80 mg of 
2 elemental iron) and zinc gluconate (10 mg of zinc) packaged in a sachet with ascorbic 
3 acid (50 mg), added to the child's meal serving (alter it was cooked) once daily. The 
4 control group received iron sprinkles (80 mg of encapsulated ferrous fumarate plus 50 mg 
5 of ascorbic acid) administered similarly, once daily. The dose of iron was identical to that 
6 which had been shown to be efficacious in our earlier study (6). Because the ferrous 
7 fumarate was lipid-coated, we documented minimal intestinal irritation from this 
8 relatively high dose of iron. 
9 
10 During the baseline assessment, a written questionnaire was administered to collect 
11 demographic, nutritional, and health data for each infant. Field workers visited infants at 2- 
12 week intervals alter the baseline visit, for a total of 5 visits. At each visit, a questionnaire 
13 regarding side effects (diarrhea, constipation, and general discomfort), ease of use and 
14 adherence over the preceding 7 days was completed. Questions related to ease of use 
15 included whether children objected to taking the iron and whether microencapsulated 
16 ferrous fumarate changed the colour, taste or texture of the infants' food. To evaluate 
17 adherence, during each visit, the number of used (empty) sachets was counted.. At each 
18 visit, fieldworkers provided parents with verbal educational reinforcement to maximize 
19 adherence to the intervention. 
20 Anthropometric measurements, including weight and height were completed 
21 during baseline and final visits as previously described (6). Capillary blood samples at 
22 baseline and final visits were obtained from a finger prick using aseptic techniques, and 
23 hemoglobin concentration was determined on the spot using a portable HEMOCUE B- 
9 
1 hemoglobin photometer (Hemocue Inc, Angelholm, Sweden) by trained technicians-using 
2 standardized techniques (17). Malaria parasite smears were taken (at the final visit only), 
3 and 500 pL blood samples were collected and preserved in ice-lined cold boxes. Blood 
4 samples were returned to the base station within 6 hours of collection, where the plasma 
5 was separated by centrifugation (10 minutes at 1300 RPM) before storage at -40°C. 
6 Serum ferritin was assayed in duplicate by a commercial enzyme-linked immunosorbent 
7 assay (ELISA), using a Spectro Ferritin Kit (Ramco Laboratories, Houston, TX) (18). 
8 Baseline and final ferritin samples from an individual subject were assayed on the same 
9 day (in a single batch) on one 96-well microtitre plate to minimize inter-assay variation. 
10 An external reference standard (Lyphochek Anaemia Control, Bio-Rad, Anaheim, CA) 
11 was assayed in duplicate on each microtitre plate for the ferritin assay. Plasma zinc 
12 concentration was determined by inductively coupled plasma mass spectrophotometry 
13 (ICP-MS) (19). 
14 
15 Sample size and power 
16 Based on a literature review and data from our previous study in Ghana, in which 
17 initial mean height-for-age z-score was -1.36 1 1.12, we expected that zinc 
18 supplementation would improve the z-score by 0.49 standard deviation units. Using an ct 
19 = 0.05 and power = 0.80 the estimated sample size was 112 subjects per group (20). 
20 Assuming a 20 % dropout rate, we planned to recruit 135 infants per group. 
21 
10 
1 Data processing and analysis 
2 Data were entered in Visual Fox Pro 6.0 (Microsoft Corporation), verified, and 
3 checked for range and consistency with customized data-entry and processing programs 
4 (Microsoft Access 97, Microsoft Corporation) as previously described (6). Data were 
5 analyzed with Statistical Analysis Software, version 8.0 (SAS Institute, Inc, Carey, NC). 
6 Paired t tests were used to analyze the change in plasma zinc and anthropometric 
7 measurements, as well as hemoglobin and ferritin, over time. Différences between groups 
8 in anthropometric measurements, plasma zinc, hemoglobin and ferritin, at the beginning 
9 and the end of the study were assessed by ANOVA (with proc GLM). Analysis of 
10 ferritin values was conducted on log-transformed data because of their skewed frequency 
11 distribution. The proportion of children who went from an anemic to a non-anemic state 
12 (hemoglobin >100 g/L) and from iron depleted to an iron replete state (ferritin >12 gg/L) 
13 was compared between the groups with chi-square analysis. McNemar's test was run to 
14 compare change in anemia and ferritin status at the beginning and end of the study. The 
15 acceptable level of statistical significance for all tests was p<0.05. 
16 
17 Ethics approval and consent 
18 Ethics approval was obtained from The Hospital for Sick Children (Toronto, 
19 Canada), the London School of Hygiene and Tropical Medicine (London, UK), and 
20 Ghana's Ministry of (Kintampo, Ghana). 
21 Oral consent to conduct the study in the Kintampo district was obtained from the 
22 District Assembly of Elected Representatives; in each village from village elders; and 
23 individual signed consent was obtained from the mothers of infants in the study. 
11 
1 Results 
2 After the screening survey, a total of 529 infants were found to be eligible for the 
3 study. 57.5% (304 infants) had hemoglobin concentrations between 70.0 g/L and 99.9 
4 g/L. Their mean age was 10.3 ± 2.5 months. Infants were randomized into 2 groups 
5 (Figure). 65 (21.4%) of the 304 infants did not attend the final assessment visit. 
6 Consequently, a total of 239 infants completed the final assessment, including 
7 anthropometric measurements and blood sampling. 
8 At baseline there were no significant différences in mean [SD] plasma zinc 
9 (p=0.58), age (p=0.78), hemoglobin (p=0.95) or ferritin (p=0.44) values between the 
10 treatment groups. 
11 
12 Anthropometric measurements 
13 There was no effect of group, gender or their interaction on initial and final z- 
14 score values. The mean weight-for-age, height-for-age and weight-for-height z-scores at 
15 baseline and final were all below zero (table 1). There were no différences between 
16 groups at baseline and end. Both groups had a significant decrease in mean weight-for- 
17 age and weight-for-height z-scores between baseline and final. Infants in the `Iron + zinc' 
18 group had a significant decrease in their mean height-for-age z-score (p=0.001), whereas 
19 there was no significant decrease in the `Fe- alone' group (p=0.099). There was a 
20 significant negative association between initial age and final mean weight-for-age 
21 (p=0.02) and weight-for-height z-scores (p=0.02) among the entire sample population. 
22 
23 Plasma Zinc Response 
12 
1 At baseline, the mean plasma zinc concentrations were similar between groups 
2 (Table 2). From baseline to the end of the study the mean plasma zinc concentration 
3 decreased significantly in both groups although there was a trend toward higher mean 
4 zinc concentrations in the `Fe + zinc' group at the end. 
5 
6 At baseline there was no différence between the groups in the proportion of 
7 infants with low plasma zinc values (p=0.4601). Overall, 43/223 (19.3%) had plasma 
zinc values below 10.7 gmol/L (normal range 11.5 -22.2 µmol/L for infants under the age 
9 of 1 year and 10.7 - 20.0 µmol/L for infants >1 year; HSC reference values). The 
10 proportion of infants with zinc values below 10.7µmol/L increased significantly in the 
11 'Iron' only group from 23/108 (21.3%) at baseline to 39/108 (36.1%) at the end 
12 (p=0.016). 
13 
14 Hemoglobin response 
15 There was no effect of initial hemoglobin, group, gender or age on final 
16 hemoglobin. In both groups, there was a significant increase in hemoglobin concentration 
17 from baseline to the end of the study (p< 0.0001; table 3). Overall, 164/239 (68.6%) of 
18 infants advanced from an anemic to a non-anemic state (hemoglobin values >100 g/L). 
19 The hemoglobin concentration in the `Iron' group was significantly higher than the "Iron 
20 + zinc' group at the end of the study (p=0.024). The rate of recovery was higher in the 
21 `Iron' group 86/115 (74.8%) than in the `Iron + zinc' group 78/124 (62.9%) (p = 0.048). 
22 Data were also analyzed to determine the percentage of infants who positively 
23 responded to iron treatment (a positive response was defined as an increase in 
13 
1 hemoglobin of 10 g/L or greater at the final blood sample). In the `Iron group, 89/115 
2 (77.4%) of the infants responded; in the `Iron + zinc' group, 84/124 (67.7%) responded 
3 (p=0.028). The relative risk of remaining anemic alter two months of treatment was 0.74 
4 times lower for the 'Iron' group (95% CI 0.54 - 1.02; p=0.049). 
5 
6 Ferritin response 
7 At baseline and at the end, geometric mean ferritin values were similar between the two 
8 groups (p= 0.44; table 4). There was a significant increase in both after the 2-month 
9 intervention (p<0.0001). The variance for ferritin values was wide at both baseline and at 
10 the end of the study, as is commonly found in malaria endemic regions. (21). At baseline 
11 there was no difference in the proportion of infants with iron depletion (defined as ferritin 
12 <12µg/L) between treatment groups (p=0.49). McNemar's analysis showed that there 
13 was a significant decrease in the number of infants with iron depletion after two months 
14 of treatment within both groups. In the'Iron' group the rate of iron depletion decreased 
15 from 36/92 (39.13%) at baseline to 22/92 (23.91%) at the end (p=0.0043) and from 
16 49/110 (44.5%) to 17/110 (15.45%) in the'Iron + Zn' group (p<0.0001). The rate of 
17 decrease observed in the zinc supplemented group was significantly greater (p<0.0001). 
18 
19 
20 Malaria status 
21 178/286 (62.24%) infants tested positive for malaria parasites. Infants who tested 
22 positive for malaria were more likely to be anemic in both groups (p< 0.0001). There was 
23 no difference in malaria status différent between groups. 
14 
1 Compliance 
2 Over the two-month intervention, 82.1 % of the infants received sprinkles at least 
3 5 times a week. Only 3.4% of parents reported having any problems using sprinkles. Of 
4 those who reported problems, only 1.8% reported that they had an unpleasant odor while 
5 80.5% reported that the sprinkles changed the colour of their infant's food (much like the 
effect of adding a condiment such as pepper to food). Fewer than 3% of all caregivers 
7 gave the sprinkles to a `non-study' child and 69.7% reported using the full contents of the 
8 sachet all of the time. All infants were breast-feeding at the start of the study and 
9 continued breast-feeding during the two-month period, although not exclusively. None of 




2 In the current study, we proposed that zinc was the limiting nutrient for the 
3 promotion and maintenance of linear growth and that supplementation with iron would 
4 further predispose to zinc deficiency and growth faltering, while zinc supplementation 
5 would sustain growth. Continued growth faltering was observed in both groups, thus 
6 zinc-supplementation did not improve growth. It is likely, therefore, that growth faltering 
7 is due to multiple factors in addition to marginal zinc status. 
8 With the single exception of the height-for-age z-score in the unsupplemented 
9 group, weight-for-age, weight-for-height and height-for-age z-scores decreased 
10 significantly in both groups over the study period.Lir-growth faltering was, however, 
11 greater in the zinc supplemented group. This suggests that zinc was not the limiting factor 
12 for linear growth. The majority of infants had adequate zinc status at baseline despite 
13 their food supply that was limited in zinc and high in zinc-binding phytate. Others have 
14 made similar observations (22). We believe that there are four possible explanations for 
15 this observation. Firstly, zinc is likely preserved when growth is limited. A rapidly 
16 growing infant needs more nutrients than a slowly growing one. Thus if growth is limited 
17 because of inadequate energy, for example, zinc needs may be concomitantly decreased. 
18 Secondly, increased stool losses of zinc from diarrhea is often a predisposing cause of 
19 zinc deficiency (7). The frequency of diarrhea in infants in the current study was not 
20 high, possibly because the study was conducted during the `dry season'. Thirdly, zinc 
21 status as assessed by plasma zinc concentration is of limited value because of its poor 
22 sensitivity and specificity to changes in dietary zinc and the inability to adequately 
23 control for postprandial variation and infection (23). Finally, it has been suggested that as 
16 
1 dietary intake becomes limited, endogenous zinc losses are homeostatically decreased 
2 (24). One or more of these reasons may explain the preservation of zinc status at baseline. 
3 It is notable that infants in the unsupplemented group were able to maintain their 
4 initial height-for-age z-scores without further significant growth faltering, while the zinc- 
5 supplemented group did not. This refutes our original hypothesis that iron supplementation 
6 alone was the major contributing factor to linear growth faltering. Alternatively, it suggests 
7 that the iron may have had a protective effect on further faltering, possibly through the 
8 greater improvement of iron status in the unsupplemented group. The impact of iron 
9 supplementation on growth could not be directly assessed in this study because, for ethical 
10 reasons, a placebo group of anemic infants was not included. The effect of iron 
11 supplementation on linear growth has been equivocal with nome reports describing 
12 enhanced growth and others the opposite (25). 
13 Like others, we observed a decrease in mean weight-for-age and weight-for- 
14 height z-scores in infants between 6 and 24 months of age (25,26). Factors that could 
15 have affected growth included infant and maternai stores of nutrients at birth, multiple 
16 deficiencies of macro- and micronutrients, and the impact of infections diseases (25). Our 
17 results showed a significant negative association between initial age and final 
18 underweight z-scores. These results imply that with increasing age, infants may not have 
19 met their dietary energy and nutrient requirements. Similar results were recently 
20 described in Ghana, where weight-for-length z-scores significantly decreased between 
21 ages 2 to 12 months (22). These observations are consistent with Brown and Dewey's 
22 conclusions that unfortified cereal-based complementary foods are inadequate total 
23 sources of nutrition for breast-feeding infants in the first years of life (27). 
17 
1 A significant decrease in mean plasma zinc concentrations was observed in both 
2 groups over the two-month study. However, the decrease was smaller and only 
3 marginally significant in the zinc-supplemented group (p=0.046). This would suggest 
4 that either the amount of zinc provided in the sachet or the bioavailability of the zinc 
5 compound was insufficient to maintain zinc status during the two-month study period or 
6 that the intervention period was too short. Dirren et al recently documented a significant 
7 increase in plasma zinc concentrations in children supplemented with 10 mg of zinc/day 
8 compared to a placebo, but over a 15-month period. Thus duration of supplementation 
9 may be a contributing factor (28). Lartey et al in Ghana, observed an inverse relationship 
10 between dietary available zinc and plasma zinc concentrations in a similar group of 
11 infants (29). When the estimate was adjusted for calcium, phytate and animal protein, the 
12 inverse relationship was relinquished. Thus, the bioavailability of zinc, when added to 
13 food as a powdered sprinkle, is likely strongly influenced by the content of other 
14 nutrients in the food to which it is added. 
15 We had originally hypothesized that iron supplementation alone depressed zinc 
16 absorption leading to linear growth faltering. The mechanism by which iron and zinc 
17 compete for absorption is not fully understood. Results of past research on the effect of 
18 dietary iron on zinc absorption are conflicting. Studies have shown that iron-fortified 
19 infant foods did not interfère with zinc absorption at Fe:Zn molar ratios of as high as 57:1 
20 (30,31). However, there is evidence that iron provided at supplementation levels may 
21 have an adverse effect on zinc absorption when Fe:Zn ratios exceed 2:1 (12,32). 
22 Furthermore, studies on the effect of prenatal iron supplements have found a decrease in 
23 fractional zinc absorption when iron was provided at amounts as small as 18 mg/d (32- 
18 
1 35). In the current study, the Fe:Zn molar ratio was relatively high at 9:1. There is no way 
2 of determining whether iron affected zinc absorption. 
3 Although the primary purpose of this study was to examine the effect of 
4 supplementary zinc on linear growth, a secondary objective was to confirm the positive 
5 effect of microencapsulated ferrous fumarate sprinkles on the treatment of anemia, as had 
6 been previously shown (6). In the current study we confirmed our earlier observations 
7 that iron sprinkles are an efficacious alternative to treating anemia in infants. In fact, the 
8 overall rate of successful treatment in the current study was even higher than in our 
9 original report. However, the rate of successful treatment of anemia in the iron-alone 
10 group was higher. The différence remained alter adjusting for age, initial hemoglobin 
11 and plasma zinc levels and malaria status. Dijkhuizen et al reported a similar antagonistic 
12 interaction on combined supplementation when compared to iron alone, which was also 
13 more effective in reducing the prevalence of anemia in Indonesian infants (36). These 
14 results imply that iron absorption was greater in infants receiving iron supplements 
15 without zinc. Inhibition of iron absorption in the zinc-supplemented group may have been 
16 a result of zinc competing with iron for the saine receptor sites on intestinal mucosal cells 
17 (37). Although a few studies have demonstrated an effect of zinc on iron absorption when 
18 Zn:Fe molar proportions were equal (38,39), there is no data on the effect of zinc on iron 
19 absorption when iron molar proportions exceed those of zinc. 
20 Results of this study indicate that in a controlled setting, micronutrient sprinkles 
21 with iron and zinc do not prevent linear growth faltering in anemic infants, although 
22 sprinkles are very successful in treating anemia. Early growth faltering in this population 
23 is likely of multifactorial origin. Sprinkles with iron alone did not contribute to an 
19 
1 increased risk of linear growth faltering and although the addition of zinc had a 
2 marginally negative effect on linear growth, one must be careful not to over-interpret 
3 these results. Had the study lasted for longer than 2 months, we may have seen a positive 
4 effect of zinc supplementation on growth as has been previously reported (40-42). 
5 Further research is in progress to directly examine the interaction between iron and zinc 
6 in sprinkles using stable isotope methodology. 
20 
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304 children enrolled 
Hb: 85.3 ± 10.6 
225 children exciuded 
I-b: 110. 1 ± 7.8 
Iron atone 
144 children 
Hb: 84.7 ± 11.5 
29 children 
Lost to follow-up 
Iron and Zinc 
160 children 
Hb: 85.7 ± 9.6 
36 children 
Lost to follow-up 
115 children 
Hb: 108.1 ± 15.5 
1 
124 children 
Hb: 103.5 ± 15.8 
2 Figure 1. Trial Profile 
26 
1 Table 1: Anthropometry as determined by z-score values for weight- and height-for-age 
2 and weight for height at baseline and at the end of the two-month intervention. 
3 (i) Weight-for-Age Z-score 
Group Iron Iron + Zinc P-value 
Baseline -1.80 ± 1.14 -1.69 ±1.01 0.4243 
Final -1.95 ± 1.09 -1.89 ± 0.93 0.6898 
Différences -0.14 ± 0.47 -0.20 ± 0.42 0.3033 
p = 0.0022 p < 0.0001 
4 N= 230 paired samples 
5 
6 (ii) Height-for-Age Z-scores 
Group Iron Iron + Zinc P-value 
Baseline -1.81 ± 1.12 -1.70 ± 1.14 0.4890 
Final -1.86 ± 1.11 -1.81 ± 1.10 0.7321 
Différences -0.05 ± 0.32 -0.10 ± 0.34 0.2244 
p = 0.0985 p = 0.0011 
27 
1 (iii) Weight-for-Height Z-scores 
Group Fe Fe + zinc P-value 
Baseline -0.65 f 0.93 -0.60 ± 0.86 0.5863 
Final -0.92 ± 0.93 -0.88 ± 0.71 0.6773 
Différences -0.27 ± 0.54 -0.29 ± 0.50 0.7801 







Table 2. Mean plasma zinc concentration by treatment group at baseline 
and two months later 




Baseline 14.04 ± 4.42 14.36 ± 4.40 0.585 
Final 12.44±3.29 13.36±3.81 0.056 
Différences -1.60 ± 4.90 -1.00 ± 5.33 0.3877 
p=0.0010 p=0.0461 
5 *Values are means ± SD 
29 
1 Table 3. Mean hemoglobin values at baseline and alter the two-month intervention *. 
2 




Baseline 87.4 ± 8.2 87.4 ± 8.5 0.9527 
Final 108.1 + 15.5 103.5 + 15.8 0.0235 
Différences 20.7 + 15.3 16.1 + 16.4 0.0282 
p : 0.0001 p:5 0.0001 
3 
4 * Values are means + SD. 
5 
30 
1 Table 4: Geometric mean ferritin values and range, by treatment group, at baseline atid 









Baseline 16.3 13.7 0.4416 
(0.2-316.8) (0.03-365.2) 
Final 37.4 51.0 0.2926 
(1.2 -390.1) (1.4-386.1) 
Différences t 21.1 37.3 0.1140 
p<.0001 p<.0001 
5 *Data are geometric means and range; analysis was done with log-transformed values 
6 since ferritin values are not normally distributed. t Mean ferritin increased significantly 
7 from baseline to the final visit in both groups (p<0.001). Normal values are 12-400 µg/L 
8 (48). Cut off values used: 400 (µg/L) 
9 
